This press release is a modified version of the official Sleep Club Press Release that can be found here. Please read the official release for more information. This version of the press release does not present any new information or information that is different from that contained in the official press release. It only serves to clearly highlight CURE Pharmaceutical's partnership with Sleep Club in order to better inform our investors.

LOS ANGELES, September 12th 2018 -- CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and development company, today announced the launch of its second sleep aid product powered by its multi-layer oral thin film technology CUREfilm™, in partnership with Sleep Club, a wellness and destination brand where healthy sleep fuels an inspired awake life.

In the official press release here,  Sleep Club announced the official launch today of joinsleepclub.com - an online wellness destination offering original content and carefully curated products for a good night’s sleep, including the Sleep Stripzzz.

 

Sleep Stripzz powered by CUREfilm oral thin film


Sleep Stripzzz, CURE’s all-natural sleep and recovery aid, contain a blend of melatonin, naturally occurring amino acids, b-caryophyllene – a plant terpene and beneficial vitamins that promote balanced sleep patterns without being habit-forming. The proprietary CUREfilm delivery system combines these sleep-promoting ingredients and recovery aids to rapidly achieve deep, restful slumber and a rejuvenated awakening.

About CURE Pharmaceutical 
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit www.curepharmaceutical.com


About Sleep Club
Sleep Club, at the intersection where a healthy sleep life fuels an inspired awake life, offers original content, curated resources and products that celebrate sleeping, dreaming and waking up. Headquartered in Los Angeles, Sleep Club can be found at www.joinsleepclub.com

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. There are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, the ability to successfully market our products, the difficulty in predicting the timing or outcome of other product research and development efforts, potential product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


CURE Public Relations Contact:
Ashley Ray
Olmstead Williams Communication
[email protected]

P. 310-824-9000